Liu Yincheng, Wang Yichun, Xu Qitong, Zhou Xiang, Qin Zhiqiang, Chen Chen, Zhang Qijie, Tian Ye, Zhang Chao, Li Xiao, Qin Chao
Department of Urology, The First Affiliated Hospital of Nanjing Medical University First Clinical Medical College of Nanjing Medical University Department of Urology, The affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, China.
Medicine (Baltimore). 2017 Oct;96(43):e8113. doi: 10.1097/MD.0000000000008113.
We performed this meta-analysis to provide a comprehensive evaluation of the role of MicroRNA-210 (miR-210) expression on the overall survival (OS) rate of cancers.
We searched for relevant available literatures on miR-210 and cancer until November 1st, 2016 on the databases PubMed, EMBASE, Cochrane Library, and Science Direct database. We calculated the pooled hazard ratio (HR) with 95% confidence intervals (CIs) for OS, which compared the high and low expression levels of miR-210 in patients of the available studies. Subgroup analysis was performed to evaluate the specific role of miR-210 in ethnicity and the type of cancers. Publication bias was evaluated using Begg funnel plots and Egger regression test.
Overall, 19 studies were involved in this meta-analysis. The result indicated that upregulated miR-210 might be associated with poor OS outcome in various carcinomas, with the pooled HR of 1.80 (95% CI: 1.29-2.51). When stratified by disease, significant results were detected in breast cancer (HR = 2.67, 95% CI: 1.24-5.76) and glioma (HR = 2.42, 95% CI: 1.32-4.43). Besides, in the subgroup analysis by ethnicity, significant results were detected only in Asian populations (HR = 2.14, 95% CI: 1.37-3.34).
The present meta-analysis suggests that high expressed miR-210 is significantly associated with OS in cancer patients, which has the potential to be a prognostic marker in cancers.
我们进行了这项荟萃分析，以全面评估微小RNA - 210（miR - 210）表达对癌症总生存率（OS）的作用。
我们在PubMed、EMBASE、Cochrane图书馆和科学Direct数据库中检索截至2016年11月1日的有关miR - 210与癌症的相关可用文献。我们计算了总生存率的合并风险比（HR）及95%置信区间（CI），用于比较现有研究中患者miR - 210的高表达水平和低表达水平。进行亚组分析以评估miR - 210在种族和癌症类型中的具体作用。使用Begg漏斗图和Egger回归检验评估发表偏倚。
总体而言，19项研究纳入了这项荟萃分析。结果表明，miR - 210上调可能与各种癌症的OS结果较差相关，合并HR为1.80（95%CI：1.29 - 2.51）。按疾病分层时，在乳腺癌（HR = 2.67，95%CI：1.24 - 5.76）和神经胶质瘤（HR = 2.42，95%CI：1.32 - 4.43）中检测到显著结果。此外，在按种族进行的亚组分析中，仅在亚洲人群中检测到显著结果（HR = 2.14，95%CI：1.37 - 3.34）。
本荟萃分析表明，高表达的miR - 210与癌症患者的OS显著相关，其有可能成为癌症的预后标志物。
